Abstract:Background and Purpose NLRP3 inflammasome activation is involved in many inflammatory diseases, however, no small‐molecule inhibitors of NLRP3 have been clinically used so far. Discovery of natural NLRP3 inhibitors may be beneficial to the design and development of molecules targeting NLRP3. Alantolactone (ALA) is a natural compound isolated from a traditional Chinese medicinal plant with anti‐inflammatory activity, but the precise target of ALA remains unclear. Experimental Approach The inhibitory activity of 150 natural compounds against NLRP3‐driven IL‐1β production was screened in macrophages. Mice models of gouty arthritis and acute lung injury were used to determine the efficacy of the potential compound. Key Results Among 150 compounds in an in‐house natural products bank, ALA was found to possess the highest inhibitory activity against LPS + ATP‐induced IL‐1β production in macrophages. We demonstrated that ALA suppressed the IL‐1β secretion, the caspase‐1 activation, and pyroptosis in LPS + ATP‐challenged macrophages. Further studies showed that ALA directly bound to the NACHT domain of NLRP3 to inhibit the activation and assembly of NLRP3 inflammasome. The molecular simulation showed that Arg335 in NLRP3 might be a critical residue for ALA binding, leading to suppression of NLRP3‐NEK7 interaction. The in vivo studies validated that ALA significantly alleviated NLRP3‐driven inflammatory diseases, including acute lung injury and gouty arthritis. Conclusion and Implications In summary, we identified ALA as a natural inhibitor of NLRP3 inflammasome by directly targeting NLRP3 NACHT domain. ALA shows great potential in the treatment of NLRP3‐driven diseases and the development of novel NLRP3 inhibitors.

Discovery and Development of NLRP3 Inhibitors Targeting the LRR Domain to Disrupt NLRP3-NEK7 Interaction for the Treatment of Rheumatoid Arthritis

Discovery and Optimization of 4-Oxo-2-thioxo-thiazolidinones As NOD-like Receptor (NLR) Family, Pyrin Domain-Containing Protein 3 (NLRP3) Inhibitors.

Deep-Learning-Driven Discovery of SN3-1, a Potent NLRP3 Inhibitor with Therapeutic Potential for Inflammatory Diseases

Discovery of Novel Biaryl Urea Derivatives Against IL-1β Release with Low Toxicity Based on NEK7 Inhibitor

Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders

Discovery of NLRP3 Inhibitors Using Machine Learning: Identification of a Hit Compound to Treat NLRP3 Activation-Driven Diseases.

Discovery of 4-((E)-3,5-dimethoxy-2-((E)-2-nitrovinyl)styryl)aniline derivatives as potent and orally active NLRP3 inflammasome inhibitors for colitis

Discovery of Triazinone Derivatives as Novel, Specific, and Direct NLRP3 Inflammasome Inhibitors for the Treatment of DSS-Induced Ulcerative Colitis

Therapeutic Potential of Targeting the NLRP3 Inflammasome in Rheumatoid Arthritis

Novel Isoalantolactone-Based Derivatives as Potent NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization

Design, synthesis and biological evaluation of novel diphenylamine analogues as NLRP3 inflammasome inhibitors

RRx-001 Ameliorates Inflammatory Diseases by Acting As a Potent Covalent NLRP3 Inhibitor

An RRx-001 Analogue With Potent Anti-NLRP3 Inflammasome Activity but Without High-Energy Nitro Functional Groups

Discovery of alantolactone as a natural NLRP3 inhibitor to alleviate NLRP3‐driven inflammatory diseases in mice

Discovery of Novel Syk/PDGFR-α/c-Kit Inhibitors As Multi-Targeting Drugs to Treat Rheumatoid Arthritis.

Identification of a covalent NEK7 inhibitor to alleviate NLRP3 inflammasome-driven metainflammation

Discovery of novel biphenyl-sulfonamide analogues as NLRP3 inflammasome inhibitors

Discovery of Novel Pterostilbene-Based Derivatives as Potent and Orally Active NLRP3 Inflammasome Inhibitors with Inflammatory Activity for Colitis

Discovery of Novel Dual Bruton's Tyrosine Kinase (BTK) and Janus Kinase 3 (JAK3) Inhibitors as A Promising Strategy for Rheumatoid Arthritis

Transformable peptide blocks NF-κB/IκBα pathway through targeted coating IκBα against rheumatoid arthritis

Design, Synthesis, and Bioevaluation of Novel NLRP3 Inhibitor with IBD Immunotherapy from the Virtual Screen